Exagen Files for $69M IPO | GenomeWeb

NEW YORK (GenomeWeb) – Autoimmune rheumatic disease diagnostics firm Exagen Diagnostics filed a preliminary prospectus on Friday for an initial public offering of up to $69 million.

The company has not yet priced its shares or said how many shares it plans to offer. It said that it anticipates its stock to trade on the Nasdaq Global Market under ticker symbol "EXDX."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.